Keloids Treatment Global Market Report 2024

The global keloids treatment market has grown strongly in recent years. It will grow from $3.91 billion in 2023 to $4.14 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to high prevalence of keloids, growing awareness keloid treatments, increasing incidence of wound and injury-related cases, rise in aesthetic surgeries.

The global keloids treatment market is expected to see steady growth in the next few years. It will grow to $4.93 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to increasing expenditure on personal care products, government initiatives, increasing emphasis on scar prevention strategies, investments on keloids treatments. Major trends in the forecast period include advancements in treatment modalities, innovation in medical technologies, adanced minimally invasive procedures on keloids treatment, combination therapies, laser technology, scar management products.

Anticipated growth in the keloid treatment market is driven by the rising incidence of wound and injury cases. Wounds, which entail physical injury or harm to the body's tissues, typically involve breaks in the skin and result from various factors such as accidents, surgical procedures, burns, or traumatic events. The escalation in the number of reported wounds contributes to the formation of keloids, thereby increasing the demand for effective treatment options. This surge in cases also fosters heightened awareness regarding keloid-related complications, stimulates advancements in research, and encourages collaboration among medical professionals. For example, data from the U.S. Bureau of Labor Statistics in November 2022 revealed a 6.3% increase in the total reported injury cases, reaching 2.2 million cases in 2021, compared to 2.1 million cases in 2020. Furthermore, the injury rate rose, with private industry employers reporting 2.3 cases per 100 full-time equivalent (FTE) workers in 2021, up from 2.2 cases in 2020. Therefore, the growing incidence of wound and injury cases is expected to drive the growth of the keloid treatment market.

The Keloid Treatment Market is Anticipated to Grow Due to Increasing Interest in Non-Surgical Aesthetic Procedures. Non-surgical aesthetics, which are non-invasive cosmetic treatments aimed at improving one's appearance without surgery, are becoming increasingly popular. Healthcare providers utilize non-surgical aesthetic techniques such as laser therapy, cryotherapy, and dermal fillers to mitigate the appearance and symptoms of keloid scars, which can include reducing inflammation, redness, and vascularization. For example, statistics from the Aesthetic Society, a US-based organization specializing in plastic and cosmetic surgery, revealed a 44% increase in non-surgical procedures in 2021. Furthermore, the use of combination lasers and dermal fillers in procedures reached 431,485 and 1,857,339, respectively, in 2021, showing a 32% and 4% increase. This growing interest in non-surgical aesthetic treatments is expected to be a driving factor for the keloid treatment market's growth.

The growth of the keloid treatment market during the forecast period is hampered by the restricted treatment options. The effectiveness of keloid treatment is often constrained due to the limited availability of treatment modalities. This limitation is further exacerbated by the high rates of keloid recurrence and potential delays in seeking treatment. For instance, in 2023, according to the Mayo Foundation for Medical Education and Research (MFMER), a non-profit organization, the treatment options for keloids are limited, and surgery alone has a recurrence rate of 45% to 100% when keloids have not responded to other therapies. As a result, the limited treatment options act as a barrier to the growth of the keloid treatment market.

Prominent companies operating in the keloid treatment market are strategically focusing on the development of innovative scar management technologies, such as Scar Erase silicone strips, to attain a competitive edge. For instance, in April 2023, Scar Erase, a UK-based scar treatment company, introduced Scar Erase silicone strips as a solution for scar treatment. These strips, composed of 3 mm medical-grade silicone, have demonstrated clinical efficacy in enhancing scar appearance and facilitating healing. They are reusable, vegan, cruelty-free, and offer a convenient and cost-effective at-home scar treatment option suitable for various scar types, including hypertrophic, keloid, post-surgery, and stretch marks. The technology involves encapsulating the scar with silicone to maintain hydration and create an optimal healing environment. This approach reduces collagen formation, improves scar texture, color, and height, delivering both effectiveness and comfort.

In March 2022, Alliance Pharma PLC, a UK-based pharmaceutical company, completed the acquisition of ScarAway from Perrigo Co. PLC for $19.4 million. This acquisition empowered Alliance Pharma to strengthen its presence in the U.S. consumer healthcare market, diversify its product portfolio, establish a global brand, boost revenue, and solidify its position as a market leader in scar treatment. ScarAway, a U.S.-based scar treatment brand specializing in keloids, played a pivotal role in this strategic move.

Major players in the keloids treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Eli Lilly and Company, Mylan N.V., Galderma S.A., Sun Pharmaceutical Industries Ltd., Molnlycke Health Care AB, Cynosure Inc., Cutera Inc., Alliance Pharma PLC, Revance Therapeutics Inc., Sensus Healthcare, Strata Skin Sciences, Avita Medical Limited, Pacific World Corporation, Mederma, Stratpharma AG, Sonoma Pharmaceuticals Inc., RXi Pharmaceuticals Inc., Biodermis, Novoxel Ltd., Scar Heal Inc., Galena Biopharma Inc.

North America was the largest region in the keloids treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in keloids treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the keloids treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The main types of keloids treatment are radiation therapy, cryotherapy, surgical treatment, laser treatment, steroid injections, interferon and others. Radiation therapy is a medical treatment that uses high doses of targeted radiation to target and destroy abnormal cells, such as keloid cells, aiming to inhibit the overgrowth of cells and reduce the size of keloids, which helps prevent keloid recurrence by damaging the cells that contribute to their formation. Keloids treatment also includes products such as elastic wraps, sprays, ointments, creams, oils, topical gels and gel sheets and others administered orally and parenterally by end users such as hospitals, homecare, dermatology clinics and others.

This report provides keloids treatment market statistics, including keloids treatment industry global market size, regional shares, competitors with a keloids treatment market share, detailed keloids treatment market segments, market trends and opportunities and any further data you may need to thrive in the keloids treatment industry. This keloids treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The keloids treatment market consists of revenues earned by entities by providing dermatology consultations, follow-up and monitoring and patient education and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The keloids treatment market also includes sales of topical creams and gels, silicone sheets and patches and dermal fillers, which are used in keloids treatment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.